Clinical Trial Update: Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating Letrozole with a CDK 4/6 inhibitor in postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer; the curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• CDK 4/6 inhibitor
• Letrozole (letrozole)

Snippet

Sponsor: Organisation for Oncology and Translational Research | Conditions: ER Positive, HER2 Negative Breast Cancer | Phase 2 | Status: UNKNOWN